UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2026
Commission File Number 001-38370
CollPlant Biotechnologies Ltd.
(Exact name of registrant as specified in its charter)
4 Oppenheimer St, Weizmann Science Park
Rehovot 7670104, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K, including the press release attached
to this Form 6-K as Exhibit 99.1, is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8
(File No. 333-229163, 333-248479, 333-263842, 333-271320 and 333-279791)
and Form F-3 (File No. 333-238731, 333-292640 and 333-297347),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.
CollPlant Biotechnologies Ltd. (the “Company”)
is announcing that it will effect a reverse share split of the Company’s ordinary shares at the ratio of 1-for-10, such that each
ten (10) ordinary shares, no par value, shall be consolidated into one (1) ordinary share, no par value. The first date when the Company’s
ordinary shares will begin trading on the Nasdaq Capital Market after implementation of the reverse split will be Friday, September 4,
2026.
No fractional ordinary shares will be issued as
a result of the reverse split. All fractional ordinary shares will be rounded to the nearest whole ordinary share. In addition, a proportionate
adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding warrants
and options entitling the holders to purchase ordinary shares. The new CUSIP number for the ordinary shares will be M2R51X124.
On September 1, 2026, the Company issued a press
release titled “Collplant Announces Reverse Share Split.” A copy of the press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.
Attached hereto and incorporated by reference herein are the following
exhibits:
| 99.1 |
|
Press Release, dated September 1, 2026. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
COLLPLANT BIOTECHNOLOGIES LTD. |
| |
|
|
| Date: September 1, 2026 |
By: |
/s/ Eran Rotem |
| |
|
Name: |
Eran Rotem |
| |
|
Title: |
Deputy CEO and Chief Financial Officer |
Exhibit 99.1
COLLPLANT ANNOUNCES REVERSE SHARE SPLIT
REHOVOT, Israel – September 1, 2026 –
CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) (“CollPlant” or the “Company”), today announced that its Board
of Directors has approved a one-for-ten reverse share split of the Company’s ordinary shares. The reverse share split is scheduled
to take effect when the Nasdaq Capital Market opens on September 4, 2026, at which point the Company’s ordinary shares will begin trading
on a split-adjusted basis under the existing ticker symbol “CLGN”. The Board’s decision follows shareholder approval granted
at the Extraordinary General Meeting of Shareholders held on August 18, 2026. The reverse split is being implemented as part of the Company’s
strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing.
Upon effectiveness of the reverse share split,
every ten shares of the Company’s outstanding ordinary shares will be converted to one ordinary share.
No fractional ordinary
shares will be issued as a result of the reverse split. All fractional ordinary shares will be rounded to the nearest whole ordinary share.
In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise
of all outstanding warrants and options entitling the holders to purchase ordinary shares. The new CUSIP number for the ordinary shares
will be M2R51X124.
Registered shareholders holding their ordinary
shares in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with the reverse share
split. For those shareholders holding physical share certificates, the Company’s transfer agent, Computershare Inc., will send instructions
for exchanging those certificates for new certificates representing the post-split number of shares.
Additional information about the reverse share
split can be found in the Company’s proxy statement filed with the Securities and Exchange Commission on July 28, 2026, attached
as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 28, 2026, a
copy of which is also available at www.sec.gov or at http://www.collplant.com.
About CollPlant
CollPlant is a regenerative and aesthetic medicine
company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics.
The Company’s products are based on its rhCollagen (recombinant human collagen) produced with CollPlant’s proprietary plant-based
genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.
In addition, CollPlant recently announced that it has signed a definitive agreement to acquire LightSolver Ltd., an Israeli deep-tech
company pioneering a fundamentally new computing architecture based on lasers.
For more information about CollPlant, visit http://www.collplant.com.
Forward-Looking Statements
This press release may include forward-looking
statements. Forward-looking statements include, but are not limited to, statements relating to effecting a reverse share split and plan
to regain compliance with the Nasdaq minimum bid price requirement for continued listing, as well as statements, other than historical
facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may
occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,”
“anticipates,” “should,” “intends,” “plans,” “will,” “expects,”
“estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based
on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions,
expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees
of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed
or implied in such statements. Many factors could cause CollPlant’s actual activities or results to differ materially from the activities
and results anticipated in forward-looking statements, including, but not limited to, the following: the proposed acquisition of LightSolver
by CollPlant and the ability of the parties to satisfy the conditions to closing the transaction and consummate the transaction on the
anticipated timeline or at all; the Company’s history of significant losses, its need to raise additional capital and its inability
to obtain additional capital on acceptable terms, or at all, including uncertainties surrounding the methods of fundraising and the Company’s
preferences regarding such methods, and including its ability to conclude a non-dilutive financing transaction; uncertainties regarding
the Company’s evaluation of strategic alternatives, including whether or when any acquisition, strategic transaction, business combination
or other opportunity may be pursued or consummated, the terms of any such transaction, and the potential impact of any such transaction
or other strategic alternative on the Company, its business, financial condition, results of operations and shareholders; the Company’s
expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to dermal and
tissue fillers, breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics;
the Company’s or Company’s strategic partners’ ability to obtain favorable pre-clinical and clinical trial results;
regulatory action with respect to rhCollagen-based bioink and medical aesthetics products or product candidates including, but not limited
to, acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the
approved indication and labeling; commercial success and market acceptance of the Company’s rhCollagen based products, in 3D Bioprinting
and medical aesthetics; the Company’s ability to establish sales and marketing capabilities or enter into agreements with third
parties and its reliance on third party distributors and resellers; the Company’s ability to establish and maintain strategic partnerships
and other corporate collaborations; the Company’s reliance on third parties to conduct some or all aspects of its product development
and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company’s
ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic
and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition
and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with
respect to the ongoing war in Israel, projected capital expenditures and liquidity, changes in the Company’s strategy and development
plans and projects, and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant
are contained under the heading “Risk Factors” included in CollPlant’s most recent annual report on Form 20-F filed
with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained
in this press release are made as of the date of this press release and reflect CollPlant’s current views with respect to future
events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as required by law.
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Email: Eran@collplant.com
